EMEA-002285-PIP02-19-M02

Table of contents

Key facts

Active substance
Marstacimab
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0443/2022
PIP number
EMEA-002285-PIP02-19-M02
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
  • Treatment of congenital haemophilia A
  • Treatment of congenital haemophilia B
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Pfizer Europe MA EEIG

Tel. +44 (0)1304 646 607
E-mail: pip_enquiries@pfizer.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating